Prognostic Value of Log Odds of Positive Lymph Nodes after Radical Surgery Followed by Adjuvant Treatment in High-Risk Cervical Cancer
Identifieur interne : 000729 ( Pmc/Curation ); précédent : 000728; suivant : 000730Prognostic Value of Log Odds of Positive Lymph Nodes after Radical Surgery Followed by Adjuvant Treatment in High-Risk Cervical Cancer
Auteurs : Jeanny Kwon [Corée du Sud] ; Keun-Yong Eom [Corée du Sud] ; In Ah Kim [Corée du Sud] ; Jae-Sung Kim [Corée du Sud] ; Young-Beom Kim [Corée du Sud] ; Jae Hong No [Corée du Sud] ; Kidong Kim [Corée du Sud]Source :
- Cancer Research and Treatment : Official Journal of Korean Cancer Association [ 1598-2998 ] ; 2015.
Abstract
The purpose of this study is to compare the prognostic efficacy of the number and location of positive lymph nodes (LN), LN ratio (LNR), and log odds of positive LNs (LODDs) in high-risk cervical cancer treated with radical surgery and adjuvant treatment.
Fifty high-risk patients who underwent radical hysterectomy and pelvic node dissection followed by adjuvant treatment were analyzed retrospectively. The patients had International Federation of Gynecology and Obstetrics (FIGO) stage IA2-IIB. Upper LN is defined as common iliac or higher LN, and LNR is the ratio of positive LNs to harvested LNs. LODDs is log odds between positive LNs and negative LNs. Radiotherapy was delivered to the whole pelvis with median 50.4 Gy/28 Fx± to the para-aortic regions. Platinum-based chemotherapy was used in most patients (93%). The median follow-up duration was 80 months.
The 5-year disease-free survival (DFS) rate was 76.1%, and the overall survival (OS) rate was 86.4%. Treatment failure occurred in 11 patients, and distant failure (DF) was the dominant pattern (90.9%). In univariate analysis, significantly lower DFSwas observed in patients with perineural invasion, ≥ 2 LN metastases, LNR ≥ 10%, upper LN metastasis, and ≥ –1.05 LODDs. In multivariate analysis, ≥ –1.05 LODDs was the only significant factor for DFS (p=0.011). Of patients with LODDs ≥ –1.05, 40.9% experienced DF. LODDs was the only significant prognostic factor for OS as well (p=0.006).
LODDs ≥ –1.05 was the only significant prognostic factor for both DFS and OS. In patients with LODDs ≥ –1.05, intensified chemotherapy might be required, considering the high rate of DF.
Url:
DOI: 10.4143/crt.2015.085
PubMed: 26194370
PubMed Central: 4843724
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000729
Links to Exploration step
PMC:4843724Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Prognostic Value of Log Odds of Positive Lymph Nodes after Radical Surgery Followed by Adjuvant Treatment in High-Risk Cervical Cancer</title><author><name sortKey="Kwon, Jeanny" sort="Kwon, Jeanny" uniqKey="Kwon J" first="Jeanny" last="Kwon">Jeanny Kwon</name><affiliation wicri:level="1"><nlm:aff id="af1-crt-2015-085">Department of Radiation Oncology, Seoul National University Hospital, Seoul,<country>Korea</country></nlm:aff><country xml:lang="fr">Corée du Sud</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Eom, Keun Yong" sort="Eom, Keun Yong" uniqKey="Eom K" first="Keun-Yong" last="Eom">Keun-Yong Eom</name><affiliation wicri:level="1"><nlm:aff id="af2-crt-2015-085">Department of Radiation Oncology, Seoul National University Bundang Hospital, Seongnam,<country>Korea</country></nlm:aff><country xml:lang="fr">Corée du Sud</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Kim, In Ah" sort="Kim, In Ah" uniqKey="Kim I" first="In Ah" last="Kim">In Ah Kim</name><affiliation wicri:level="1"><nlm:aff id="af2-crt-2015-085">Department of Radiation Oncology, Seoul National University Bundang Hospital, Seongnam,<country>Korea</country></nlm:aff><country xml:lang="fr">Corée du Sud</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Kim, Jae Sung" sort="Kim, Jae Sung" uniqKey="Kim J" first="Jae-Sung" last="Kim">Jae-Sung Kim</name><affiliation wicri:level="1"><nlm:aff id="af2-crt-2015-085">Department of Radiation Oncology, Seoul National University Bundang Hospital, Seongnam,<country>Korea</country></nlm:aff><country xml:lang="fr">Corée du Sud</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Kim, Young Beom" sort="Kim, Young Beom" uniqKey="Kim Y" first="Young-Beom" last="Kim">Young-Beom Kim</name><affiliation wicri:level="1"><nlm:aff id="af3-crt-2015-085">Department of Obstetrics and Gynecology, Seoul National University Bundang Hospital, Seongnam,<country>Korea</country></nlm:aff><country xml:lang="fr">Corée du Sud</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="No, Jae Hong" sort="No, Jae Hong" uniqKey="No J" first="Jae Hong" last="No">Jae Hong No</name><affiliation wicri:level="1"><nlm:aff id="af3-crt-2015-085">Department of Obstetrics and Gynecology, Seoul National University Bundang Hospital, Seongnam,<country>Korea</country></nlm:aff><country xml:lang="fr">Corée du Sud</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Kim, Kidong" sort="Kim, Kidong" uniqKey="Kim K" first="Kidong" last="Kim">Kidong Kim</name><affiliation wicri:level="1"><nlm:aff id="af3-crt-2015-085">Department of Obstetrics and Gynecology, Seoul National University Bundang Hospital, Seongnam,<country>Korea</country></nlm:aff><country xml:lang="fr">Corée du Sud</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">26194370</idno><idno type="pmc">4843724</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4843724</idno><idno type="RBID">PMC:4843724</idno><idno type="doi">10.4143/crt.2015.085</idno><date when="2015">2015</date><idno type="wicri:Area/Pmc/Corpus">000729</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000729</idno><idno type="wicri:Area/Pmc/Curation">000729</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000729</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Prognostic Value of Log Odds of Positive Lymph Nodes after Radical Surgery Followed by Adjuvant Treatment in High-Risk Cervical Cancer</title><author><name sortKey="Kwon, Jeanny" sort="Kwon, Jeanny" uniqKey="Kwon J" first="Jeanny" last="Kwon">Jeanny Kwon</name><affiliation wicri:level="1"><nlm:aff id="af1-crt-2015-085">Department of Radiation Oncology, Seoul National University Hospital, Seoul,<country>Korea</country></nlm:aff><country xml:lang="fr">Corée du Sud</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Eom, Keun Yong" sort="Eom, Keun Yong" uniqKey="Eom K" first="Keun-Yong" last="Eom">Keun-Yong Eom</name><affiliation wicri:level="1"><nlm:aff id="af2-crt-2015-085">Department of Radiation Oncology, Seoul National University Bundang Hospital, Seongnam,<country>Korea</country></nlm:aff><country xml:lang="fr">Corée du Sud</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Kim, In Ah" sort="Kim, In Ah" uniqKey="Kim I" first="In Ah" last="Kim">In Ah Kim</name><affiliation wicri:level="1"><nlm:aff id="af2-crt-2015-085">Department of Radiation Oncology, Seoul National University Bundang Hospital, Seongnam,<country>Korea</country></nlm:aff><country xml:lang="fr">Corée du Sud</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Kim, Jae Sung" sort="Kim, Jae Sung" uniqKey="Kim J" first="Jae-Sung" last="Kim">Jae-Sung Kim</name><affiliation wicri:level="1"><nlm:aff id="af2-crt-2015-085">Department of Radiation Oncology, Seoul National University Bundang Hospital, Seongnam,<country>Korea</country></nlm:aff><country xml:lang="fr">Corée du Sud</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Kim, Young Beom" sort="Kim, Young Beom" uniqKey="Kim Y" first="Young-Beom" last="Kim">Young-Beom Kim</name><affiliation wicri:level="1"><nlm:aff id="af3-crt-2015-085">Department of Obstetrics and Gynecology, Seoul National University Bundang Hospital, Seongnam,<country>Korea</country></nlm:aff><country xml:lang="fr">Corée du Sud</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="No, Jae Hong" sort="No, Jae Hong" uniqKey="No J" first="Jae Hong" last="No">Jae Hong No</name><affiliation wicri:level="1"><nlm:aff id="af3-crt-2015-085">Department of Obstetrics and Gynecology, Seoul National University Bundang Hospital, Seongnam,<country>Korea</country></nlm:aff><country xml:lang="fr">Corée du Sud</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Kim, Kidong" sort="Kim, Kidong" uniqKey="Kim K" first="Kidong" last="Kim">Kidong Kim</name><affiliation wicri:level="1"><nlm:aff id="af3-crt-2015-085">Department of Obstetrics and Gynecology, Seoul National University Bundang Hospital, Seongnam,<country>Korea</country></nlm:aff><country xml:lang="fr">Corée du Sud</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author></analytic><series><title level="j">Cancer Research and Treatment : Official Journal of Korean Cancer Association</title><idno type="ISSN">1598-2998</idno><idno type="eISSN">2005-9256</idno><imprint><date when="2015">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><sec><title>Purpose</title><p>The purpose of this study is to compare the prognostic efficacy of the number and location of positive lymph nodes (LN), LN ratio (LNR), and log odds of positive LNs (LODDs) in high-risk cervical cancer treated with radical surgery and adjuvant treatment.</p></sec><sec><title>Materials and Methods</title><p>Fifty high-risk patients who underwent radical hysterectomy and pelvic node dissection followed by adjuvant treatment were analyzed retrospectively. The patients had International Federation of Gynecology and Obstetrics (FIGO) stage IA2-IIB. Upper LN is defined as common iliac or higher LN, and LNR is the ratio of positive LNs to harvested LNs. LODDs is log odds between positive LNs and negative LNs. Radiotherapy was delivered to the whole pelvis with median 50.4 Gy/28 Fx± to the para-aortic regions. Platinum-based chemotherapy was used in most patients (93%). The median follow-up duration was 80 months.</p></sec><sec><title>Results</title><p>The 5-year disease-free survival (DFS) rate was 76.1%, and the overall survival (OS) rate was 86.4%. Treatment failure occurred in 11 patients, and distant failure (DF) was the dominant pattern (90.9%). In univariate analysis, significantly lower DFSwas observed in patients with perineural invasion, ≥ 2 LN metastases, LNR ≥ 10%, upper LN metastasis, and ≥ –1.05 LODDs. In multivariate analysis, ≥ –1.05 LODDs was the only significant factor for DFS (p=0.011). Of patients with LODDs ≥ –1.05, 40.9% experienced DF. LODDs was the only significant prognostic factor for OS as well (p=0.006).</p></sec><sec><title>Conclusion</title><p>LODDs ≥ –1.05 was the only significant prognostic factor for both DFS and OS. In patients with LODDs ≥ –1.05, intensified chemotherapy might be required, considering the high rate of DF.</p></sec></div></front><back><div1 type="bibliography"><listBibl><biblStruct><analytic><author><name sortKey="Rotman, M" uniqKey="Rotman M">M Rotman</name></author><author><name sortKey="Sedlis, A" uniqKey="Sedlis A">A Sedlis</name></author><author><name sortKey="Piedmonte, Mr" uniqKey="Piedmonte M">MR Piedmonte</name></author><author><name sortKey="Bundy, B" uniqKey="Bundy B">B Bundy</name></author><author><name sortKey="Lentz, Ss" uniqKey="Lentz S">SS Lentz</name></author><author><name sortKey="Muderspach, Li" uniqKey="Muderspach L">LI Muderspach</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Song, S" uniqKey="Song S">S Song</name></author><author><name sortKey="Song, C" uniqKey="Song C">C Song</name></author><author><name sortKey="Kim, Hj" uniqKey="Kim H">HJ Kim</name></author><author><name sortKey="Wu, Hg" uniqKey="Wu H">HG Wu</name></author><author><name sortKey="Kim, Jh" uniqKey="Kim J">JH Kim</name></author><author><name sortKey="Park, Nh" uniqKey="Park N">NH Park</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kim, Wy" uniqKey="Kim W">WY Kim</name></author><author><name sortKey="Chang, Sj" uniqKey="Chang S">SJ Chang</name></author><author><name sortKey="Chang, Kh" uniqKey="Chang K">KH Chang</name></author><author><name sortKey="Yoo, Sc" uniqKey="Yoo S">SC Yoo</name></author><author><name sortKey="Chun, M" uniqKey="Chun M">M Chun</name></author><author><name sortKey="Ryu, Hs" uniqKey="Ryu H">HS Ryu</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Piura, B" uniqKey="Piura B">B Piura</name></author><author><name sortKey="Rabinovich, A" uniqKey="Rabinovich A">A Rabinovich</name></author><author><name sortKey="Friger, M" uniqKey="Friger M">M Friger</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Tsai, Cs" uniqKey="Tsai C">CS Tsai</name></author><author><name sortKey="Lai, Ch" uniqKey="Lai C">CH Lai</name></author><author><name sortKey="Wang, Cc" uniqKey="Wang C">CC Wang</name></author><author><name sortKey="Chang, Jt" uniqKey="Chang J">JT Chang</name></author><author><name sortKey="Chang, Tc" uniqKey="Chang T">TC Chang</name></author><author><name sortKey="Tseng, Cj" uniqKey="Tseng C">CJ Tseng</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lin, Hh" uniqKey="Lin H">HH Lin</name></author><author><name sortKey="Cheng, Wf" uniqKey="Cheng W">WF Cheng</name></author><author><name sortKey="Chan, Kw" uniqKey="Chan K">KW Chan</name></author><author><name sortKey="Chang, Dy" uniqKey="Chang D">DY Chang</name></author><author><name sortKey="Chen, Ck" uniqKey="Chen C">CK Chen</name></author><author><name sortKey="Huang, Sc" uniqKey="Huang S">SC Huang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kim, Hs" uniqKey="Kim H">HS Kim</name></author><author><name sortKey="Kim, Mk" uniqKey="Kim M">MK Kim</name></author><author><name sortKey="Kim, Hj" uniqKey="Kim H">HJ Kim</name></author><author><name sortKey="Han, Ss" uniqKey="Han S">SS Han</name></author><author><name sortKey="Kim, Jw" uniqKey="Kim J">JW Kim</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lee, Jw" uniqKey="Lee J">JW Lee</name></author><author><name sortKey="Kim, Bg" uniqKey="Kim B">BG Kim</name></author><author><name sortKey="Lee, Sj" uniqKey="Lee S">SJ Lee</name></author><author><name sortKey="Lee, Sh" uniqKey="Lee S">SH Lee</name></author><author><name sortKey="Park, Cs" uniqKey="Park C">CS Park</name></author><author><name sortKey="Lee, Jh" uniqKey="Lee J">JH Lee</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Compton, Cc" uniqKey="Compton C">CC Compton</name></author><author><name sortKey="Byrd, Dr" uniqKey="Byrd D">DR Byrd</name></author><author><name sortKey="Garcia Aguilar, J" uniqKey="Garcia Aguilar J">J Garcia-Aguilar</name></author><author><name sortKey="Kurtzman, Sh" uniqKey="Kurtzman S">SH Kurtzman</name></author><author><name sortKey="Olawaiye, A" uniqKey="Olawaiye A">A Olawaiye</name></author><author><name sortKey="Washington, Mk" uniqKey="Washington M">MK Washington</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Monk, Bj" uniqKey="Monk B">BJ Monk</name></author><author><name sortKey="Wang, J" uniqKey="Wang J">J Wang</name></author><author><name sortKey="Im, S" uniqKey="Im S">S Im</name></author><author><name sortKey="Stock, Rj" uniqKey="Stock R">RJ Stock</name></author><author><name sortKey="Peters, Wa" uniqKey="Peters W">WA Peters</name></author><author><name sortKey="Liu, Py" uniqKey="Liu P">PY Liu</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kidd, Ea" uniqKey="Kidd E">EA Kidd</name></author><author><name sortKey="Siegel, Ba" uniqKey="Siegel B">BA Siegel</name></author><author><name sortKey="Dehdashti, F" uniqKey="Dehdashti F">F Dehdashti</name></author><author><name sortKey="Rader, Js" uniqKey="Rader J">JS Rader</name></author><author><name sortKey="Mutch, Dg" uniqKey="Mutch D">DG Mutch</name></author><author><name sortKey="Powell, Ma" uniqKey="Powell M">MA Powell</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Demirci, S" uniqKey="Demirci S">S Demirci</name></author><author><name sortKey="Ozsaran, Z" uniqKey="Ozsaran Z">Z Ozsaran</name></author><author><name sortKey="Ozsaran, A" uniqKey="Ozsaran A">A Ozsaran</name></author><author><name sortKey="Yavas, F" uniqKey="Yavas F">F Yavas</name></author><author><name sortKey="Demircioglu, B" uniqKey="Demircioglu B">B Demircioglu</name></author><author><name sortKey="Hanhan, M" uniqKey="Hanhan M">M Hanhan</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Pecorelli, S" uniqKey="Pecorelli S">S Pecorelli</name></author><author><name sortKey="Zigliani, L" uniqKey="Zigliani L">L Zigliani</name></author><author><name sortKey="Odicino, F" uniqKey="Odicino F">F Odicino</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Takeda, N" uniqKey="Takeda N">N Takeda</name></author><author><name sortKey="Sakuragi, N" uniqKey="Sakuragi N">N Sakuragi</name></author><author><name sortKey="Takeda, M" uniqKey="Takeda M">M Takeda</name></author><author><name sortKey="Okamoto, K" uniqKey="Okamoto K">K Okamoto</name></author><author><name sortKey="Kuwabara, M" uniqKey="Kuwabara M">M Kuwabara</name></author><author><name sortKey="Negishi, H" uniqKey="Negishi H">H Negishi</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Polterauer, S" uniqKey="Polterauer S">S Polterauer</name></author><author><name sortKey="Hefler, L" uniqKey="Hefler L">L Hefler</name></author><author><name sortKey="Seebacher, V" uniqKey="Seebacher V">V Seebacher</name></author><author><name sortKey="Rahhal, J" uniqKey="Rahhal J">J Rahhal</name></author><author><name sortKey="Tempfer, C" uniqKey="Tempfer C">C Tempfer</name></author><author><name sortKey="Horvat, R" uniqKey="Horvat R">R Horvat</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Wang, J" uniqKey="Wang J">J Wang</name></author><author><name sortKey="Hassett, Jm" uniqKey="Hassett J">JM Hassett</name></author><author><name sortKey="Dayton, Mt" uniqKey="Dayton M">MT Dayton</name></author><author><name sortKey="Kulaylat, Mn" uniqKey="Kulaylat M">MN Kulaylat</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Sun, Z" uniqKey="Sun Z">Z Sun</name></author><author><name sortKey="Xu, Y" uniqKey="Xu Y">Y Xu</name></author><author><name sortKey="Li, Dm" uniqKey="Li D">DM Li</name></author><author><name sortKey="Wang, Zn" uniqKey="Wang Z">ZN Wang</name></author><author><name sortKey="Zhu, Gl" uniqKey="Zhu G">GL Zhu</name></author><author><name sortKey="Huang, Bj" uniqKey="Huang B">BJ Huang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Peters, Wa" uniqKey="Peters W">WA Peters</name></author><author><name sortKey="Liu, Py" uniqKey="Liu P">PY Liu</name></author><author><name sortKey="Barrett, Rj" uniqKey="Barrett R">RJ Barrett</name></author><author><name sortKey="Stock, Rj" uniqKey="Stock R">RJ Stock</name></author><author><name sortKey="Monk, Bj" uniqKey="Monk B">BJ Monk</name></author><author><name sortKey="Berek, Js" uniqKey="Berek J">JS Berek</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Soisson, Ap" uniqKey="Soisson A">AP Soisson</name></author><author><name sortKey="Soper, Jt" uniqKey="Soper J">JT Soper</name></author><author><name sortKey="Clarke Pearson, Dl" uniqKey="Clarke Pearson D">DL Clarke-Pearson</name></author><author><name sortKey="Berchuck, A" uniqKey="Berchuck A">A Berchuck</name></author><author><name sortKey="Montana, G" uniqKey="Montana G">G Montana</name></author><author><name sortKey="Creasman, Wt" uniqKey="Creasman W">WT Creasman</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kim, Mk" uniqKey="Kim M">MK Kim</name></author><author><name sortKey="Jo, H" uniqKey="Jo H">H Jo</name></author><author><name sortKey="Kong, Hj" uniqKey="Kong H">HJ Kong</name></author><author><name sortKey="Kim, Hc" uniqKey="Kim H">HC Kim</name></author><author><name sortKey="Kim, Jw" uniqKey="Kim J">JW Kim</name></author><author><name sortKey="Kim, Ym" uniqKey="Kim Y">YM Kim</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lee, Hj" uniqKey="Lee H">HJ Lee</name></author><author><name sortKey="Han, S" uniqKey="Han S">S Han</name></author><author><name sortKey="Kim, Ys" uniqKey="Kim Y">YS Kim</name></author><author><name sortKey="Nam, Jh" uniqKey="Nam J">JH Nam</name></author><author><name sortKey="Kim, Hj" uniqKey="Kim H">HJ Kim</name></author><author><name sortKey="Kim, Jw" uniqKey="Kim J">JW Kim</name></author></analytic></biblStruct></listBibl></div1></back></TEI><pmc article-type="research-article"><pmc-dir>properties open_access</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Cancer Res Treat</journal-id><journal-id journal-id-type="iso-abbrev">Cancer Res Treat</journal-id><journal-id journal-id-type="publisher-id">CRT</journal-id><journal-title-group><journal-title>Cancer Research and Treatment : Official Journal of Korean Cancer Association</journal-title></journal-title-group><issn pub-type="ppub">1598-2998</issn><issn pub-type="epub">2005-9256</issn><publisher><publisher-name>Korean Cancer Association</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26194370</article-id><article-id pub-id-type="pmc">4843724</article-id><article-id pub-id-type="doi">10.4143/crt.2015.085</article-id><article-id pub-id-type="publisher-id">crt-2015-085</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Prognostic Value of Log Odds of Positive Lymph Nodes after Radical Surgery Followed by Adjuvant Treatment in High-Risk Cervical Cancer</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kwon</surname><given-names>Jeanny</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="af1-crt-2015-085"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Eom</surname><given-names>Keun-Yong</given-names></name><degrees>MD</degrees><degrees>PhD</degrees><xref ref-type="corresp" rid="c1-crt-2015-085"></xref><xref ref-type="aff" rid="af2-crt-2015-085"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>In Ah</given-names></name><degrees>MD</degrees><degrees>PhD</degrees><xref ref-type="aff" rid="af2-crt-2015-085"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Jae-Sung</given-names></name><degrees>MD</degrees><degrees>PhD</degrees><xref ref-type="aff" rid="af2-crt-2015-085"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Young-Beom</given-names></name><degrees>MD</degrees><degrees>PhD</degrees><xref ref-type="aff" rid="af3-crt-2015-085"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>No</surname><given-names>Jae Hong</given-names></name><degrees>MD</degrees><degrees>PhD</degrees><xref ref-type="aff" rid="af3-crt-2015-085"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Kidong</given-names></name><degrees>MD</degrees><degrees>PhD</degrees><xref ref-type="aff" rid="af3-crt-2015-085"><sup>3</sup></xref></contrib><aff id="af1-crt-2015-085"><label>1</label>Department of Radiation Oncology, Seoul National University Hospital, Seoul,<country>Korea</country></aff><aff id="af2-crt-2015-085"><label>2</label>Department of Radiation Oncology, Seoul National University Bundang Hospital, Seongnam,<country>Korea</country></aff><aff id="af3-crt-2015-085"><label>3</label>Department of Obstetrics and Gynecology, Seoul National University Bundang Hospital, Seongnam,<country>Korea</country></aff></contrib-group><author-notes><corresp id="c1-crt-2015-085">Correspondence: Keun-Yong Eom, MD, PhD Department of Radiation Oncology, Seoul National University Bundang Hospital, 82 Gumi-ro 173beon-gil, Bundang-gu, Seongnam 13620, Korea Tel: 82-31-787-7653 Fax: 82-31-787-4019 E-mail: <email>978sarang@hanmail.net</email></corresp></author-notes><pub-date pub-type="ppub"><month>4</month><year>2016</year></pub-date><pub-date pub-type="epub"><day>14</day><month>7</month><year>2015</year></pub-date><volume>48</volume><issue>2</issue><fpage>632</fpage><lpage>640</lpage><history><date date-type="received"><day>1</day><month>3</month><year>2015</year></date><date date-type="accepted"><day>16</day><month>6</month><year>2015</year></date></history><permissions><copyright-statement>Copyright © 2016 by the Korean Cancer Association</copyright-statement><copyright-year>2016</copyright-year><license><license-p>This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-CommercialLicense (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original workis properlycited.</license-p></license></permissions><abstract><sec><title>Purpose</title><p>The purpose of this study is to compare the prognostic efficacy of the number and location of positive lymph nodes (LN), LN ratio (LNR), and log odds of positive LNs (LODDs) in high-risk cervical cancer treated with radical surgery and adjuvant treatment.</p></sec><sec><title>Materials and Methods</title><p>Fifty high-risk patients who underwent radical hysterectomy and pelvic node dissection followed by adjuvant treatment were analyzed retrospectively. The patients had International Federation of Gynecology and Obstetrics (FIGO) stage IA2-IIB. Upper LN is defined as common iliac or higher LN, and LNR is the ratio of positive LNs to harvested LNs. LODDs is log odds between positive LNs and negative LNs. Radiotherapy was delivered to the whole pelvis with median 50.4 Gy/28 Fx± to the para-aortic regions. Platinum-based chemotherapy was used in most patients (93%). The median follow-up duration was 80 months.</p></sec><sec><title>Results</title><p>The 5-year disease-free survival (DFS) rate was 76.1%, and the overall survival (OS) rate was 86.4%. Treatment failure occurred in 11 patients, and distant failure (DF) was the dominant pattern (90.9%). In univariate analysis, significantly lower DFSwas observed in patients with perineural invasion, ≥ 2 LN metastases, LNR ≥ 10%, upper LN metastasis, and ≥ –1.05 LODDs. In multivariate analysis, ≥ –1.05 LODDs was the only significant factor for DFS (p=0.011). Of patients with LODDs ≥ –1.05, 40.9% experienced DF. LODDs was the only significant prognostic factor for OS as well (p=0.006).</p></sec><sec><title>Conclusion</title><p>LODDs ≥ –1.05 was the only significant prognostic factor for both DFS and OS. In patients with LODDs ≥ –1.05, intensified chemotherapy might be required, considering the high rate of DF.</p></sec></abstract><kwd-group><kwd>Uterine cervical neoplasms</kwd><kwd>Lymph nodes</kwd><kwd>Log odds of positive lymph node</kwd><kwd>Prognosis</kwd></kwd-group></article-meta></front><floats-group><fig id="f1-crt-2015-085" orientation="portrait" position="float"><label>Fig. 1.</label><caption><p>Disease-free survival (A) and overall survival (B) according to log odds of positive lymph nodes (LODDs).</p></caption><graphic xlink:href="crt-2015-085f1"></graphic></fig><fig id="f2-crt-2015-085" orientation="portrait" position="float"><label>Fig. 2.</label><caption><p>Disease-free survival according to log odds of positive lymph nodes (LNs) (LODDs) (A), upper LN metastasis (B), lymph node ratio (LNR) (C), and number of positive LNs (D).</p></caption><graphic xlink:href="crt-2015-085f2"></graphic></fig><table-wrap id="t1-crt-2015-085" orientation="portrait" position="float"><label>Table 1.</label><caption><p>Clinical characteristics</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Characteristic</th><th valign="top" align="center" rowspan="1" colspan="1">No. (%)</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Age, median (range, yr)</bold></td><td valign="top" align="center" rowspan="1" colspan="1">51 (27 to 78)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>FIGO stage</bold></td><td valign="top" align="center" rowspan="1" colspan="1"></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"> 1A2</td><td valign="top" align="center" rowspan="1" colspan="1">2 (4.0)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"> 1B1</td><td valign="top" align="center" rowspan="1" colspan="1">24 (48.0)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"> 1B2</td><td valign="top" align="center" rowspan="1" colspan="1">10 (20.0)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"> 2A1</td><td valign="top" align="center" rowspan="1" colspan="1">9 (18.0)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"> 2A2</td><td valign="top" align="center" rowspan="1" colspan="1">1 (2.0)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"> 2B</td><td valign="top" align="center" rowspan="1" colspan="1">4 (8.0)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Histology</bold></td><td valign="top" align="center" rowspan="1" colspan="1"></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"> Squamous cell carcinoma</td><td valign="top" align="center" rowspan="1" colspan="1">38 (76.0)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"> Adenocarcinoma</td><td valign="top" align="center" rowspan="1" colspan="1">7 (14.0)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"> Mucinous adenocarcinoma</td><td valign="top" align="center" rowspan="1" colspan="1">2 (4.0)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"> Adenosquamous carcinoma</td><td valign="top" align="center" rowspan="1" colspan="1">1 (2.0)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"> Glassy cell carcinoma</td><td valign="top" align="center" rowspan="1" colspan="1">1 (2.0)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"> Mucoepidermoid carcinoma</td><td valign="top" align="center" rowspan="1" colspan="1">1 (2.0)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Deep stromal invasion (outer 1/3)</bold></td><td valign="top" align="center" rowspan="1" colspan="1"></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"> Negative</td><td valign="top" align="center" rowspan="1" colspan="1">6 (12.0)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"> Positive</td><td valign="top" align="center" rowspan="1" colspan="1">35 (70.0)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Parametrial extension</bold></td><td valign="top" align="center" rowspan="1" colspan="1"></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"> Negative</td><td valign="top" align="center" rowspan="1" colspan="1">20 (40.0)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"> Positive</td><td valign="top" align="center" rowspan="1" colspan="1">30 (60.0)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Bulky tumor (cm)</bold></td><td valign="top" align="center" rowspan="1" colspan="1"></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"> ≤ 4</td><td valign="top" align="center" rowspan="1" colspan="1">21 (42.0)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"> > 4</td><td valign="top" align="center" rowspan="1" colspan="1">29 (58.0)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Lymphovascular invasion</bold></td><td valign="top" align="center" rowspan="1" colspan="1"></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"> Negative</td><td valign="top" align="center" rowspan="1" colspan="1">11 (22.0)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"> Positive</td><td valign="top" align="center" rowspan="1" colspan="1">39 (78.0)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Perineural invasion</bold></td><td valign="top" align="center" rowspan="1" colspan="1"></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"> Negative</td><td valign="top" align="center" rowspan="1" colspan="1">43 (86.0)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"> Positive</td><td valign="top" align="center" rowspan="1" colspan="1">7 (14.0)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Pathologic N stage</bold></td><td valign="top" align="center" rowspan="1" colspan="1"></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"> N0</td><td valign="top" align="center" rowspan="1" colspan="1">12 (24.0)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"> N1</td><td valign="top" align="center" rowspan="1" colspan="1">38 (76.0)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Upper lymph node<sup><xref rid="tfn2-crt-2015-085" ref-type="table-fn">a)</xref></sup> involvement</bold></td><td valign="top" align="center" rowspan="1" colspan="1"></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"> Negative</td><td valign="top" align="center" rowspan="1" colspan="1">37 (74.0)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"> Positive</td><td valign="top" align="center" rowspan="1" colspan="1">13 (26.0)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>LN ratio (%)<sup><xref rid="tfn3-crt-2015-085" ref-type="table-fn">b)</xref></sup></bold></td><td valign="top" align="center" rowspan="1" colspan="1"></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"> < 10</td><td valign="top" align="center" rowspan="1" colspan="1">33 (66.0)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"> ≥ 10</td><td valign="top" align="center" rowspan="1" colspan="1">17 (34.0)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Log odds of positive LNs<sup><xref rid="tfn4-crt-2015-085" ref-type="table-fn">c)</xref></sup>, median (range)</bold></td><td valign="top" align="center" rowspan="1" colspan="1">-1.15 (-2.09 to -0.2)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"> ≥ -1.05</td><td valign="top" align="center" rowspan="1" colspan="1">22 (44.0)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"> < -1.05</td><td valign="top" align="center" rowspan="1" colspan="1">28 (56.0)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Pretreatment NLR, median (range)</bold></td><td valign="top" align="center" rowspan="1" colspan="1">2.09 (0.72 to 18.89)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"> < 2.1</td><td valign="top" align="center" rowspan="1" colspan="1">25 (50.0)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"> ≥ 2.1</td><td valign="top" align="center" rowspan="1" colspan="1">24 (48.0)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Adjuvant treatment</bold></td><td valign="top" align="center" rowspan="1" colspan="1"></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"> RT alone</td><td valign="top" align="center" rowspan="1" colspan="1">7 (14.0)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"> CCRT</td><td valign="top" align="center" rowspan="1" colspan="1">43 (86.0)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>SCC, median (U/mL)</bold></td><td valign="top" align="center" rowspan="1" colspan="1">2.60</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>CEA, median (ng/mL)</bold></td><td valign="top" align="center" rowspan="1" colspan="1">1.07</td></tr></tbody></table><table-wrap-foot><fn id="tfn1-crt-2015-085"><p>FIGO, International Federation of Gynecology and Obstetrics; LN, lymph node; NLR, neutrophil/lymphocyte ratio; RT, radiotherapy; CCRT, concurrent chemoradiotherapy; SCC, squamous cell carcinoma antigen; CEA, carcinoembryonic antigen.</p></fn><fn id="tfn2-crt-2015-085"><label>a)</label><p>Upper lymph node: common iliac or para-aortic lymph node,</p></fn><fn id="tfn3-crt-2015-085"><label>b)</label><p>LN ratio: No. of pathologic LNs/No. of total LNs harvested,</p></fn><fn id="tfn4-crt-2015-085"><label>c)</label><p>Log odds of positive LNs: log(No. of positive LNs/No. of negative LNs).</p></fn></table-wrap-foot></table-wrap><table-wrap id="t2-crt-2015-085" orientation="portrait" position="float"><label>Table 2.</label><caption><p>Distribution of metastatic lymph nodes (LNs) in patients with pN1 (n=38)</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="middle" rowspan="1" colspan="1"></th><th valign="middle" align="left" rowspan="1" colspan="1">Distribution of pathologic LN</th><th valign="middle" align="center" rowspan="1" colspan="1">No. (%)</th></tr></thead><tbody><tr><td valign="top" rowspan="1" colspan="1">Pelvic node dissection</td><td valign="top" align="left" rowspan="1" colspan="1">Total harvested node, median (range)</td><td valign="top" align="center" rowspan="1" colspan="1">30 (10-79)</td></tr><tr><td valign="top" rowspan="1" colspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1">Pathologic node, median (range)</td><td valign="top" align="center" rowspan="1" colspan="1">2 (1-26)</td></tr><tr><td valign="top" rowspan="1" colspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1">Obturator LN</td><td valign="top" align="center" rowspan="1" colspan="1">19 (50.0)</td></tr><tr><td valign="top" rowspan="1" colspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1">External iliac LN</td><td valign="top" align="center" rowspan="1" colspan="1">15 (41.7)</td></tr><tr><td valign="top" rowspan="1" colspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1">Internal iliac LN</td><td valign="top" align="center" rowspan="1" colspan="1">12 (31.6)</td></tr><tr><td valign="top" rowspan="1" colspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1">Common iliac</td><td valign="top" align="center" rowspan="1" colspan="1">12 (31.6)</td></tr><tr><td valign="top" rowspan="1" colspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1">Parametrial LN</td><td valign="top" align="center" rowspan="1" colspan="1">3 (7.9)</td></tr><tr><td rowspan="3" valign="top" align="left" colspan="1">Para-aortic LN examination (n=13)</td><td valign="top" align="center" rowspan="1" colspan="1">Total harvested node, median (range)</td><td valign="top" align="center" rowspan="1" colspan="1">6 (1-17)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Pathologic node, median (range)</td><td valign="top" align="center" rowspan="1" colspan="1">1 (0-9)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Para-aortic LN</td><td valign="top" align="center" rowspan="1" colspan="1">7 (18.4)</td></tr></tbody></table></table-wrap><table-wrap id="t3-crt-2015-085" orientation="portrait" position="float"><label>Table 3.</label><caption><p>Treatment toxicity</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Toxicity</th><th valign="top" align="center" rowspan="1" colspan="1">Grade 1/2</th><th valign="top" align="center" rowspan="1" colspan="1">Grade 3</th><th valign="top" align="center" rowspan="1" colspan="1">Grade 4</th></tr></thead><tbody><tr><td valign="top" rowspan="1" colspan="1"><bold>Acute</bold></td><td valign="top" align="center" rowspan="1" colspan="1"></td><td valign="top" align="center" rowspan="1" colspan="1"></td><td valign="top" align="center" rowspan="1" colspan="1"></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"> Gastrointestinal toxicity</td><td valign="top" align="center" rowspan="1" colspan="1">24 (48)</td><td valign="top" align="center" rowspan="1" colspan="1">-</td><td valign="top" align="center" rowspan="1" colspan="1">-</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"> Genitourinary toxicity</td><td valign="top" align="center" rowspan="1" colspan="1">10 (20)</td><td valign="top" align="center" rowspan="1" colspan="1">-</td><td valign="top" align="center" rowspan="1" colspan="1">-</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"> Neutropenia</td><td valign="top" align="center" rowspan="1" colspan="1">13 (26)</td><td valign="top" align="center" rowspan="1" colspan="1">4 (8)</td><td valign="top" align="center" rowspan="1" colspan="1">14 (28)</td></tr><tr><td valign="top" rowspan="1" colspan="1"><bold>Chronic</bold></td><td valign="top" align="center" rowspan="1" colspan="1"></td><td valign="top" align="center" rowspan="1" colspan="1"></td><td valign="top" align="center" rowspan="1" colspan="1"></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"> Lymphedema</td><td valign="top" align="center" rowspan="1" colspan="1">18 (36)</td><td valign="top" align="center" rowspan="1" colspan="1">-</td><td valign="top" align="center" rowspan="1" colspan="1">-</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"> Peripheral neuropathy</td><td valign="top" align="center" rowspan="1" colspan="1">5 (10)</td><td valign="top" align="center" rowspan="1" colspan="1">-</td><td valign="top" align="center" rowspan="1" colspan="1">-</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"> Urinary incontinence</td><td valign="top" align="center" rowspan="1" colspan="1">2 (4)</td><td valign="top" align="center" rowspan="1" colspan="1">-</td><td valign="top" align="center" rowspan="1" colspan="1">-</td></tr></tbody></table><table-wrap-foot><fn id="tfn6-crt-2015-085"><p>Values are presented as number (%). Two patients underwent surgical intervention for adhesive ileus or vesicovaginal fistula.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t4-crt-2015-085" orientation="portrait" position="float"><label>Table 4.</label><caption><p>Univariate analysis for disease-free survival (DFS) and overall survival (OS)</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="middle" align="left" rowspan="1" colspan="1">Variable</th><th valign="middle" align="center" rowspan="1" colspan="1">5-yr DFS (%)</th><th valign="middle" align="center" rowspan="1" colspan="1">p-value<sup><xref rid="tfn8-crt-2015-085" ref-type="table-fn">a)</xref></sup></th><th valign="middle" align="center" rowspan="1" colspan="1">5-yr OS (%)</th><th valign="middle" align="center" rowspan="1" colspan="1">p-value<sup><xref rid="tfn8-crt-2015-085" ref-type="table-fn">a)</xref></sup></th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Age (yr)</bold></td><td valign="top" align="center" rowspan="1" colspan="1"></td><td valign="top" align="center" rowspan="1" colspan="1"></td><td valign="top" align="center" rowspan="1" colspan="1"></td><td valign="top" align="center" rowspan="1" colspan="1"></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"> ≤ 50</td><td valign="top" align="center" rowspan="1" colspan="1">78.0</td><td valign="top" align="center" rowspan="1" colspan="1">0.831</td><td valign="top" align="center" rowspan="1" colspan="1">91.4</td><td valign="top" align="center" rowspan="1" colspan="1">0.460</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"> > 50</td><td valign="top" align="center" rowspan="1" colspan="1">74.1</td><td valign="top" align="center" rowspan="1" colspan="1"></td><td valign="top" align="center" rowspan="1" colspan="1">82.5</td><td valign="top" align="center" rowspan="1" colspan="1"></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Histology</bold></td><td valign="top" align="center" rowspan="1" colspan="1"></td><td valign="top" align="center" rowspan="1" colspan="1"></td><td valign="top" align="center" rowspan="1" colspan="1"></td><td valign="top" align="center" rowspan="1" colspan="1"></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"> Squamous cell carcinoma</td><td valign="top" align="center" rowspan="1" colspan="1">74.3</td><td valign="top" align="center" rowspan="1" colspan="1">0.718</td><td valign="top" align="center" rowspan="1" colspan="1">85.0</td><td valign="top" align="center" rowspan="1" colspan="1">0.724</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"> Others</td><td valign="top" align="center" rowspan="1" colspan="1">83.3</td><td valign="top" align="center" rowspan="1" colspan="1"></td><td valign="top" align="center" rowspan="1" colspan="1">91.7</td><td valign="top" align="center" rowspan="1" colspan="1"></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Deep stromal invasion</bold></td><td valign="top" align="center" rowspan="1" colspan="1"></td><td valign="top" align="center" rowspan="1" colspan="1"></td><td valign="top" align="center" rowspan="1" colspan="1"></td><td valign="top" align="center" rowspan="1" colspan="1"></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"> Negative</td><td valign="top" align="center" rowspan="1" colspan="1">100</td><td valign="top" align="center" rowspan="1" colspan="1">0.149</td><td valign="top" align="center" rowspan="1" colspan="1">100</td><td valign="top" align="center" rowspan="1" colspan="1">0.311</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"> Positive</td><td valign="top" align="center" rowspan="1" colspan="1">69.0</td><td valign="top" align="center" rowspan="1" colspan="1"></td><td valign="top" align="center" rowspan="1" colspan="1">83.4</td><td valign="top" align="center" rowspan="1" colspan="1"></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Bulky tumor (cm)</bold></td><td valign="top" align="center" rowspan="1" colspan="1"></td><td valign="top" align="center" rowspan="1" colspan="1"></td><td valign="top" align="center" rowspan="1" colspan="1"></td><td valign="top" align="center" rowspan="1" colspan="1"></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"> ≤ 4</td><td valign="top" align="center" rowspan="1" colspan="1">78.6</td><td valign="top" align="center" rowspan="1" colspan="1">0.686</td><td valign="top" align="center" rowspan="1" colspan="1">82.4</td><td valign="top" align="center" rowspan="1" colspan="1">0.700</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"> > 4</td><td valign="top" align="center" rowspan="1" colspan="1">74.5</td><td valign="top" align="center" rowspan="1" colspan="1"></td><td valign="top" align="center" rowspan="1" colspan="1">88.7</td><td valign="top" align="center" rowspan="1" colspan="1"></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Lymphovascular invasion</bold></td><td valign="top" align="center" rowspan="1" colspan="1"></td><td valign="top" align="center" rowspan="1" colspan="1"></td><td valign="top" align="center" rowspan="1" colspan="1"></td><td valign="top" align="center" rowspan="1" colspan="1"></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"> Negative</td><td valign="top" align="center" rowspan="1" colspan="1">100</td><td valign="top" align="center" rowspan="1" colspan="1">0.053</td><td valign="top" align="center" rowspan="1" colspan="1">100</td><td valign="top" align="center" rowspan="1" colspan="1">0.157</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"> Positive</td><td valign="top" align="center" rowspan="1" colspan="1">69.1</td><td valign="top" align="center" rowspan="1" colspan="1"></td><td valign="top" align="center" rowspan="1" colspan="1">82.2</td><td valign="top" align="center" rowspan="1" colspan="1"></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Parametrial invasion</bold></td><td valign="top" align="center" rowspan="1" colspan="1"></td><td valign="top" align="center" rowspan="1" colspan="1"></td><td valign="top" align="center" rowspan="1" colspan="1"></td><td valign="top" align="center" rowspan="1" colspan="1"></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"> Negative</td><td valign="top" align="center" rowspan="1" colspan="1">89.1</td><td valign="top" align="center" rowspan="1" colspan="1">0.084</td><td valign="top" align="center" rowspan="1" colspan="1">95.0</td><td valign="top" align="center" rowspan="1" colspan="1">0.195</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"> Positive</td><td valign="top" align="center" rowspan="1" colspan="1">67.3</td><td valign="top" align="center" rowspan="1" colspan="1"></td><td valign="top" align="center" rowspan="1" colspan="1">79.8</td><td valign="top" align="center" rowspan="1" colspan="1"></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Perineural invasion</bold></td><td valign="top" align="center" rowspan="1" colspan="1"></td><td valign="top" align="center" rowspan="1" colspan="1"></td><td valign="top" align="center" rowspan="1" colspan="1"></td><td valign="top" align="center" rowspan="1" colspan="1"></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"> Negative</td><td valign="top" align="center" rowspan="1" colspan="1">82.2</td><td valign="top" align="center" rowspan="1" colspan="1">0.012</td><td valign="top" align="center" rowspan="1" colspan="1">87.0</td><td valign="top" align="center" rowspan="1" colspan="1">0.801</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"> Positive</td><td valign="top" align="center" rowspan="1" colspan="1">38.1</td><td valign="top" align="center" rowspan="1" colspan="1"></td><td valign="top" align="center" rowspan="1" colspan="1">83.3</td><td valign="top" align="center" rowspan="1" colspan="1"></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Pathologic N stage</bold></td><td valign="top" align="center" rowspan="1" colspan="1"></td><td valign="top" align="center" rowspan="1" colspan="1"></td><td valign="top" align="center" rowspan="1" colspan="1"></td><td valign="top" align="center" rowspan="1" colspan="1"></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"> N0</td><td valign="top" align="center" rowspan="1" colspan="1">100</td><td valign="top" align="center" rowspan="1" colspan="1">0.059</td><td valign="top" align="center" rowspan="1" colspan="1">100</td><td valign="top" align="center" rowspan="1" colspan="1">0.197</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"> N1</td><td valign="top" align="center" rowspan="1" colspan="1">69.6</td><td valign="top" align="center" rowspan="1" colspan="1"></td><td valign="top" align="center" rowspan="1" colspan="1">83.0</td><td valign="top" align="center" rowspan="1" colspan="1"></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>No. of LN invasion</bold></td><td valign="top" align="center" rowspan="1" colspan="1"></td><td valign="top" align="center" rowspan="1" colspan="1"></td><td valign="top" align="center" rowspan="1" colspan="1"></td><td valign="top" align="center" rowspan="1" colspan="1"></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"> < 2</td><td valign="top" align="center" rowspan="1" colspan="1">90.0</td><td valign="top" align="center" rowspan="1" colspan="1">0.030</td><td valign="top" align="center" rowspan="1" colspan="1">87.0</td><td valign="top" align="center" rowspan="1" colspan="1">0.801</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"> ≥ 2</td><td valign="top" align="center" rowspan="1" colspan="1">59.6</td><td valign="top" align="center" rowspan="1" colspan="1"></td><td valign="top" align="center" rowspan="1" colspan="1">83.3</td><td valign="top" align="center" rowspan="1" colspan="1"></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Upper LN<sup><xref rid="tfn9-crt-2015-085" ref-type="table-fn">b)</xref></sup> involvement</bold></td><td valign="top" align="center" rowspan="1" colspan="1"></td><td valign="top" align="center" rowspan="1" colspan="1"></td><td valign="top" align="center" rowspan="1" colspan="1"></td><td valign="top" align="center" rowspan="1" colspan="1"></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"> Negative</td><td valign="top" align="center" rowspan="1" colspan="1">88.2</td><td valign="top" align="center" rowspan="1" colspan="1">0.002</td><td valign="top" align="center" rowspan="1" colspan="1">90.8</td><td valign="top" align="center" rowspan="1" colspan="1">0.197</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"> Positive</td><td valign="top" align="center" rowspan="1" colspan="1">46.2</td><td valign="top" align="center" rowspan="1" colspan="1"></td><td valign="top" align="center" rowspan="1" colspan="1">75.0</td><td valign="top" align="center" rowspan="1" colspan="1"></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>LN ratio (%)<sup><xref rid="tfn10-crt-2015-085" ref-type="table-fn">c)</xref></sup></bold></td><td valign="top" align="center" rowspan="1" colspan="1"></td><td valign="top" align="center" rowspan="1" colspan="1"></td><td valign="top" align="center" rowspan="1" colspan="1"></td><td valign="top" align="center" rowspan="1" colspan="1"></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"> < 10</td><td valign="top" align="center" rowspan="1" colspan="1">89.7</td><td valign="top" align="center" rowspan="1" colspan="1">0.003</td><td valign="top" align="center" rowspan="1" colspan="1">92.8</td><td valign="top" align="center" rowspan="1" colspan="1">0.092</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"> ≥ 10</td><td valign="top" align="center" rowspan="1" colspan="1">52.3</td><td valign="top" align="center" rowspan="1" colspan="1"></td><td valign="top" align="center" rowspan="1" colspan="1">75.3</td><td valign="top" align="center" rowspan="1" colspan="1"></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Log odds of positive LNs<sup><xref rid="tfn11-crt-2015-085" ref-type="table-fn">d)</xref></sup></bold></td><td valign="top" align="center" rowspan="1" colspan="1"></td><td valign="top" align="center" rowspan="1" colspan="1"></td><td valign="top" align="center" rowspan="1" colspan="1"></td><td valign="top" align="center" rowspan="1" colspan="1"></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"> ≥ -1.05</td><td valign="top" align="center" rowspan="1" colspan="1">54.2</td><td valign="top" align="center" rowspan="1" colspan="1">< 0.001</td><td valign="top" align="center" rowspan="1" colspan="1">71.5</td><td valign="top" align="center" rowspan="1" colspan="1">0.006</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"> < -1.05</td><td valign="top" align="center" rowspan="1" colspan="1">96.4</td><td valign="top" align="center" rowspan="1" colspan="1"></td><td valign="top" align="center" rowspan="1" colspan="1">100</td><td valign="top" align="center" rowspan="1" colspan="1"></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Pretreatment NLR</bold></td><td valign="top" align="center" rowspan="1" colspan="1"></td><td valign="top" align="center" rowspan="1" colspan="1"></td><td valign="top" align="center" rowspan="1" colspan="1"></td><td valign="top" align="center" rowspan="1" colspan="1"></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"> < 2.1</td><td valign="top" align="center" rowspan="1" colspan="1">74.0</td><td valign="top" align="center" rowspan="1" colspan="1">0.646</td><td valign="top" align="center" rowspan="1" colspan="1">85.8</td><td valign="top" align="center" rowspan="1" colspan="1">0.875</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"> ≥ 2.1</td><td valign="top" align="center" rowspan="1" colspan="1">83.3</td><td valign="top" align="center" rowspan="1" colspan="1"></td><td valign="top" align="center" rowspan="1" colspan="1">86.8</td><td valign="top" align="center" rowspan="1" colspan="1"></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>SCC</bold></td><td valign="top" align="center" rowspan="1" colspan="1"></td><td valign="top" align="center" rowspan="1" colspan="1"></td><td valign="top" align="center" rowspan="1" colspan="1"></td><td valign="top" align="center" rowspan="1" colspan="1"></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"> ≤ 2</td><td valign="top" align="center" rowspan="1" colspan="1">87.8</td><td valign="top" align="center" rowspan="1" colspan="1">0.145</td><td valign="top" align="center" rowspan="1" colspan="1">93.8</td><td valign="top" align="center" rowspan="1" colspan="1">0.256</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"> > 2</td><td valign="top" align="center" rowspan="1" colspan="1">72.1</td><td valign="top" align="center" rowspan="1" colspan="1"></td><td valign="top" align="center" rowspan="1" colspan="1">82.3</td><td valign="top" align="center" rowspan="1" colspan="1"></td></tr></tbody></table><table-wrap-foot><fn id="tfn7-crt-2015-085"><p>LN, lymph node; NLR, neutrophil/lymphocyte ratio; SCC, squamous cell carcinoma antigen.</p></fn><fn id="tfn8-crt-2015-085"><label>a)</label><p>p-value by log-rank test,</p></fn><fn id="tfn9-crt-2015-085"><label>b)</label><p>Upper LN included common iliac or para-aortic lymph node,</p></fn><fn id="tfn10-crt-2015-085"><label>c)</label><p>LN ratio: No. of pathologic LNs/No. of total LNs harvested,</p></fn><fn id="tfn11-crt-2015-085"><label>d)</label><p>Log odds of positive LNs: log(No. of positive LNs/No. of negative LNs).</p></fn></table-wrap-foot></table-wrap></floats-group></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Pmc/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000729 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Curation/biblio.hfd -nk 000729 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= Pmc
|étape= Curation
|type= RBID
|clé= PMC:4843724
|texte= Prognostic Value of Log Odds of Positive Lymph Nodes after Radical Surgery Followed by Adjuvant Treatment in High-Risk Cervical Cancer
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Curation/RBID.i -Sk "pubmed:26194370" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Curation/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |